Eating disorder centers are facing an influx of people with weight-loss prescriptions. Experts say doctors are overprescribing them and some patients are taking them in secret.

Initially, Dr Reddy's will focus on launching the generic semaglutide in Canada, India, Brazil, Turkey, and other emerging ...

HIMS stock up 16% on Wednesday, continuing month-long gains. Novo Nordisk ends partnership, cites misleading marketing and ...

Novo Nordisk announced it is cutting ties with telehealth giant Hims & Hers Health, pulling its blockbuster drug Wegovy from the platform after accusing the company of selling “illegitimate, knockoff ...

Swoopes is one of the true pioneers of women’s basketball. She was the first player signed to the WNBA in 1997, led the Houston Comets to four straight championships, and was a cornerstone of Team USA ...

Significant’ weight returned weeks after stopping drug, say researchers who advise patients to adjust expectations.

India’s Dr Reddy’s Laboratories Ltd. is gearing up to launch a generic version of semaglutide — the active ingredient in Novo ...

The company initially plans to launch the generic version in Canada, India, Brazil, Turkey and other emerging markets, ...

Viatris Inc.'s proposed copy of Novo Nordisk A/S’ Wegovy doesn’t infringe a patent on using the once-weekly obesity drug ...

Dr Reddy's Laboratories plans to launch a cheaper copycat version of Novo Nordisk's blockbuster weight-loss drug Wegovy in 87 ...

Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance coverage has fueled a risky but growing “gray” market for purchasing active ...

Dr. Reddy’s Laboratories ( NYSE: RDY) is preparing to launch a generic version of semaglutide, the active ingredient in Novo ...